Reimbursement rates for Secukinumab

Secukinumab (The original drug Secukinumab) has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may vary. The price of each box of 150mg/ML is around RMB 1,000. The original drug Secukinumab has also been launched overseas. The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic drugs of Secukinumab produced and launched.